The compound LY2444296, which blocks the kappa opioid receptor, significantly reduces alcohol consumption in animal models of alcohol dependence. This study suggests LY2444296 could be a breakthrough in treating alcohol use disorder (AUD) by targeting the brain's KOP system, implicated in addiction and withdrawal symptoms.
The compound LY2444296, which blocks the kappa opioid receptor, significantly reduces alcohol consumption in animal models of alcohol dependence. This study suggests LY2444296 could be a breakthrough in treating alcohol use disorder (AUD) by targeting the brain's KOP system, implicated in addiction and withdrawal symptoms.
Share this Article
Recommended